Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07797335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

Name: AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications — clinical trial record (NCT07797335)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AMBITION 7

StatusRecruiting

PhasePhase 3

SponsorNovo Nordisk A/S

Started2026-08-24

View on ClinicalTrials.gov ↗

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

Trial Details

NCT Number	NCT07797335
Lead Sponsor	Novo Nordisk A/S
Conditions	Type 2 Diabetes, Cardiovascular Risk
Enrollment	1,778 participants
Start Date	2026-08-24
Primary Completion	2028-07-31 (estimated)
Study Completion	2028-09-20 (estimated)
Updated on ClinicalTrials.gov	2026-09-01